• Home
  •  / WindMIL Therapeutics

WindMIL Therapeutics

OverviewSuggest Edit

WindMIL Therapeutics is a company focusing on oncology cell therapy. It develops a class of cell therapies called MILs (marrow infiltrating lymphocytes) derived from memory T cells found in the bone marrow.
TypePrivate
Founded2016
HQBaltimore, MD, USMap
Websitewindmiltx.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2021)25(-3%)
Cybersecurity ratingBMore

WindMIL Therapeutics Office Locations

WindMIL Therapeutics has offices in Baltimore and Philadelphia
Baltimore, MD, US (HQ)
1812 Ashland Ave #100
Philadelphia, PA, US
3675 Market St #200
Show all (2)

WindMIL Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2016

WindMIL Therapeutics total Funding

$42.5 m

WindMIL Therapeutics latest funding size

$32.50 m

Time since last funding

3 years ago

WindMIL Therapeutics investors

Camden Partners, Domain Associates, Qiming Venture Partners, Medivate Partners, Scott H. Cohen, FoxKiser
WindMIL Therapeutics's latest funding round in June 2018 was reported to be $32.5 m. In total, WindMIL Therapeutics has raised $42.5 m
Show all financial metrics

WindMIL Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

Learn more about our premium products
SecurityScorecard logo

WindMIL Therapeutics Online and Social Media Presence

WindMIL Therapeutics's Trends

Embed Graph

WindMIL Therapeutics News and Updates

November 09, 2020

WindMIL Therapeutics Presents New Marrow-Infiltrating Lymphocytes (MILs®) Data Demonstrating Broad Therapeutic Promise for Solid Tumor Cancers

PHILADELPHIA and BALTIMORE, Nov. 09, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs®) products for cancer immunotherapy, today presented new data demonstrating the therapeutic promise for MILs as a potential cancer immunother…
October 20, 2020

WindMIL Therapeutics Announces Marrow-Infiltrating Lymphocytes (MILs®) Data Selected for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

PHILADELPHIA and BALTIMORE, Oct. 20, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs®) products for cancer immunotherapy, today announced that data regarding MILs® as a potential cancer immunotherapy for hematological and soli…
October 05, 2020

WindMIL Therapeutics to Present at 2020 Virtual Cell & Gene Meeting on the Mesa

PHILADELPHIA and BALTIMORE, Oct. 05, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs®) products for cancer immunotherapy, today announced that Chairman and Chief Executive Officer Don Hayden will present at the annual Cell &am…

 WindMIL Therapeutics Frequently Asked Questions

  • When was WindMIL Therapeutics founded?

    WindMIL Therapeutics was founded in 2016.

  • How many employees does WindMIL Therapeutics have?

    WindMIL Therapeutics has 25 employees.

  • Who are WindMIL Therapeutics competitors?

    Competitors of WindMIL Therapeutics include Gliknik, Aurora Biopharma and PIN Pharma.

  • Where is WindMIL Therapeutics headquarters?

    WindMIL Therapeutics headquarters is located at 1812 Ashland Ave #100, Baltimore.

  • Where are WindMIL Therapeutics offices?

    WindMIL Therapeutics has offices in Baltimore and Philadelphia.

  • How many offices does WindMIL Therapeutics have?

    WindMIL Therapeutics has 2 offices.